Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practical Updates on Advances in CLL and MCL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Chong

The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibro…

Daniel Wolff

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

University of Colorado Division of Hematology

M. Kamdar

When Not to Watch and Wait: Emerging Strategies in the Treatment of …

Indy Hematology Review

M. Williams

Making Sense of 1L Treatment Options in MCL

SOHO Brazil 2024

T. Phillips

Update on Cellular Therapy in Lymphoma

Total Health

B. Randolph

ASH 2023 Summary: "Highlights and Key Takeaways in MCL"

Insights from 2023 ASH Annual Meeting

P. Jain

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

SOHO 2023: What Is High Risk MCL and How Should We Treat It

SOHO 2023 Eleventh Annual Meeting

A. Kumar

ASH 2023 Summary: "The Best of MCL - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

V. Yazbeck

Standards of Care and Future Directions in MCL

Martin Dreyling

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin

State of the Art and Next Questions: Management of MCL

SOHO Highlights: State of the Art and Next Questions

A. Goy